ALLO-ASC-DFU
Phase 3Biologic
ALLO-ASC-DFU is one of 34 biologic programs targeting Diabetic Foot. It is currently in Phase 3.
2
Indications
14
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
210 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Zyvox
PfizerPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Isordil
AstraZenecaPhase 3
Cubicin
BBaxter Healthcare Corporation
Phase 3
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Urokinase
Mmedac GmbH
Phase 3
Bemiparin
RRovi Pharmaceuticals Laboratories
Phase 3
Biochaperone Combo
AAdocia
Phase 3
Beta-Glucan
BBiotec Pharmacon ASA
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial6 trials
Diabetic Foot4 trials
Efficacy and Safety2 trials
Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALLO-ASC-DFU. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAnterogen Co., Ltd.